Retrospective study of the efficacy of hormonal therapy for advanced or recurrent low-grade endometrial stromal sarcoma

Retrospective study of the efficacy of hormonal therapy for advanced or recurrent low-grade endometrial stromal sarcoma - Retrospective study of the efficacy of hormonal therapy for advanced or recurrent low-grade endometrial stromal sarcoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050780

Enrollment

Registered

2023-04-10

Start date

2023-01-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable advanced or recurrent low-grade endometrial stromal sarcoma

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who treated with hormonal therapy (medroxyprogesterone acetate: MPA, aromatase inhibitor, gonadotropin releasing hormone: GnRH agonist) for advanced or recurrent LGESS between January 2011 and December 2021. Patients with histologically diagnosed LGESS. Patients who can submit a HE-stained preparation for central pathological diagnosis.

Exclusion criteria

Exclusion criteria: Patients with active, overlapping cancers that may affect the endpoints.

Design outcomes

Primary

Measure	Time frame
progression free survival (PFS)	—

Secondary

Measure	Time frame
overall survival (OS) objective response rate (ORR) treatment duration safety	—

Countries

Japan

Contacts

Public ContactAtsuko Kawamura

Shizuoka Cancer Center division of gynecology

a.kawamura@scchr.jp055-989-5222

Outcome results